A placebo-controlled trial of nimodipine with cyclophosphamide/cisplatin for the treatment of advanced ovarian cancer

Not Applicable

Completed

• Conditions: Ovarian cancer; Cancer

• Registration Number: ISRCTN66284161
• Lead Sponsor: Cancer Research UK (CRUK) (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 1993-01-01
• Study Start: 2001-07-01
• Last Update Posted: 11 February 2019

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 0

Inclusion Criteria

1. Confirmed diagnosis of invasive epithelial ovarian cancer
2. International Federation of Gynaecology and Obstetrics (FIGO) stages Tc - Tv
3. 18-70 years old
4. Performance Status less than or equal to 2
5. White Blood Cells at least 4 x 10^9/l
6. Platelets at least 120 x 10^9/l
7. Creatinine or Ethylene Diamine Tetraacetic Acid (EDTA) clearance greater than or equal to 60 ml/min
8. Normal Bilirubin
9. Serum glutamic-oxaloacetic transaminase (SGOT)/Serum glutamic pyruvic transaminase (SGPT) less than or equal to twice normal limit
10. No previous chemotherapy or radiotherapy

Exclusion Criteria

Not provided at time of registration

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ot provided at time of registration

Secondary Outcome Measures

Name	Time	Method
ot provided at time of registration